KB
NKTR icon

Kimelman & Baird’s Nektar Therapeutics NKTR Stock Holding History

Kimelman & Baird’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$908 Hold
13
– – ﹤0.01% 247
2026
Q1 		$936 Hold
13
– – ﹤0.01% 248
2025
Q4 		$550 Hold
13
– – ﹤0.01% 252
2025
Q3 		$740 Hold
13
– – ﹤0.01% 286
2025
Q2 		$336 Hold
13
– – ﹤0.01% 331
2025
Q1 		$136 Hold
13
– – ﹤0.01% 343
2024
Q4 		$186 Hold
13
– – ﹤0.01% 350
2024
Q3 		$260 Hold
13
– – ﹤0.01% 354
2024
Q2 		$248 Buy
+13
New +$274 ﹤0.01% 362

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kimelman & Baird's NKTR Position: Q2 2026 in Review

Kimelman & Baird held its Nektar Therapeutics (NKTR) position steady in Q2 2026 at 13 shares worth $908. The position accounts for ﹤0.01% of the portfolio, ranked #247.

Kimelman & Baird first reported a position in NKTR in Q2 2024 and has held it in 9 quarters since. The position peaked at $936 in Q1 2026. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Kimelman & Baird held 13 shares of Nektar Therapeutics worth $908 as of Q2 2026.
  • Kimelman & Baird left its Nektar Therapeutics share count unchanged in Q2 2026.
  • Nektar Therapeutics made up ﹤0.01% of Kimelman & Baird's portfolio in Q2 2026, its #247 holding.
  • Kimelman & Baird first reported a position in Nektar Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Kimelman & Baird's Nektar Therapeutics position peaked at $936 in Q1 2026.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Kimelman & Baird's 13F filing for Q2 2026, filed 5 Aug 2026.